| 替莫唑胺联合卡培他滨在神经内分泌肿瘤中的临床应用 |
| |
| 引用本文： | 连妤瑾,宋丽杰,孙燕,樊青霞.替莫唑胺联合卡培他滨在神经内分泌肿瘤中的临床应用[J].中国肿瘤临床,2019,46(15):808-812. |
| |
| 作者姓名： | 连妤瑾 宋丽杰 孙燕 樊青霞 |
| |
| 作者单位： | 郑州大学第一附属医院肿瘤科(郑州市 450052) |
| |
| 摘 要： | 近年来，神经内分泌肿瘤（neuroendocrine neoplasm，NEN）的治疗受到越来越多的关注，但多数治疗方案未能使肿瘤产生客观缓解。生长抑素类似物、依维莫司和舒尼替尼能显著延长患者无进展生存期（progression-free survival，PFS），但客观缓解率（objective response rate，ORR）较低。以链脲霉素为基础的化疗方案因毒性较大且在国内尚未上市，在临床使用中受到限制。一些小样本研究提示替莫唑胺联合卡培他滨（CAPTEM）有较高的ORR和较长的PFS。然而，目前鲜见CAPTEM方案的系统性综述。本文通过近年来国内外文献报道，对CAPTEM方案治疗神经内分泌肿瘤的理论基础、疗效、疗效预测生物标志物、具体给药方案及不良反应等方面作一综述。
|
| 关 键 词： | 神经内分泌肿瘤 治疗 替莫唑胺 卡培他滨 |
| 收稿时间： | 2019-05-31 |
Clinical application of temozolomide combined with capecitabine in neuroendocrine tumors |
| |
| Affiliation: | Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China |
| |
| Abstract: | In recent years, the treatment of neuroendocrine neoplasm (NEN) has gained more and more attention; however, few treatment options lead to an objective relief. Somatostatin analogs, everolimus, and sunitinib significantly prolong the progression-free survival (PFS) but can result in a low objective response rate (ORR). The clinical use of streptozotocin-based chemotherapy regimen is limited because of its toxicity and thus is not marketed in China. Some studies with small sample sizes suggest that temozolomide combined with capecitabine (CAPTEM) can result in a higher ORR and longer PFS. However, there is currently no systematic review of the CAPTEM regimen. In this paper, the theoretical basis, efficacy, biomarkers for efficacy predicting, specific drug regimen, and adverse reactions of the CAPTEM regimen for treating neuroendocrine tumors have been reviewed based on studies in recent years. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
